Headlines about Ocera Therapeutics (NASDAQ:OCRX) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ocera Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.0140674781133 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Ocera Therapeutics (OCRX) traded up $0.02 during midday trading on Tuesday, reaching $1.79. The company had a trading volume of 969,300 shares, compared to its average volume of 1,105,401. Ocera Therapeutics has a 1 year low of $0.52 and a 1 year high of $2.95. The firm has a market capitalization of $47.46, a PE ratio of -1.85 and a beta of 2.46.
Ocera Therapeutics (NASDAQ:OCRX) last issued its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.24) EPS for the quarter, meeting the consensus estimate of ($0.24). equities analysts forecast that Ocera Therapeutics will post -0.93 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This article was reported by BBNS and is the property of of BBNS. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://baseballnewssource.com/markets/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-ocera-therapeutics-ocrx-stock-price/1820860.html.
About Ocera Therapeutics
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
Receive News & Ratings for Ocera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.